1,335 results on '"Uemura, Hirotsugu"'
Search Results
2. Exploring the relationship between ulcerative colitis, colorectal cancer, and prostate cancer
3. C-Reactive Protein-Albumin Ratio Predicts Objective Response to Enfortumab Vedotin in Metastatic Urothelial Carcinoma
4. The efficacy of second-line tyrosine kinase inhibitor for patients with metastatic non-clear cell renal cell carcinoma following first-line immune-oncology combination therapy
5. Durable Response to Enfortumab Vedotin Compared to Re-challenging Chemotherapy in Metastatic Urothelial Carcinoma After Checkpoint Inhibitors
6. Comparison of the efficacy of enfortumab vedotin between patients with metastatic urothelial carcinoma who were treated with avelumab or pembrolizumab: real-world data from a multi-institutional study in Japan
7. Post Hoc Analysis of Rapid and Deep Prostate-specific Antigen Decline and Patient-reported Health-related Quality of Life in SPARTAN and TITAN Patients with Advanced Prostate Cancer
8. Current status and future perspectives of the managements of metastatic hormone-sensitive prostate cancer
9. Clinical Outcomes of Patients with High-risk Metastatic Hormone-naïve Prostate Cancer: A 3-year Interim Analysis of the Observational J-ROCK Study
10. External beam radiotherapy combination is a risk factor for bladder cancer in patients with prostate cancer treated with brachytherapy
11. Apalutamide plus androgen deprivation therapy in clinical subgroups of patients with metastatic castration-sensitive prostate cancer: A subgroup analysis of the randomised clinical TITAN study
12. The pressure flow study investigation of pathophysiology of post-micturition dribble in male patients
13. Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022
14. Predictive factors for the efficacy of abiraterone acetate therapy in high-risk metastatic hormone-sensitive prostate cancer patients
15. EphA2 on urinary extracellular vesicles as a novel biomarker for bladder cancer diagnosis and its effect on the invasiveness of bladder cancer
16. Real-world efficacy and safety of nivolumab plus ipilimumab in untreated metastatic renal cell carcinoma, and the impact of previous nephrectomy on clinical outcome: Japanese multi-institutional retrospective study
17. Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022
18. Prognostic value of immune phenotype and PD-L1 status in recurrent or metastatic renal cell carcinoma: an exploratory analysis of the ARCHERY study
19. First-line therapy for metastatic renal cell carcinoma: A propensity score-matched comparison of efficacy and safety
20. Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
21. Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021
22. Real-world safety and effectiveness of nivolumab for advanced renal cell carcinoma in Japan: a post-marketing surveillance
23. Prostate‐specific antigen kinetics in Asian patients with metastatic castration‐sensitive prostate cancer treated with apalutamide in the TITAN trial: A post hoc analysis.
24. Targeted Investigational Treatment Analysis of Novel Anti‐androgen (TITAN) study: ultralow prostate‐specific antigen decline with apalutamide plus androgen‐deprivation therapy.
25. UFO registry: final analysis of baseline data from patients with advanced prostate cancer in Asia.
26. A cross‐species analysis of fecal microbiomes in humans and mice reveals similarities and dissimilarities associated with prostate cancer risk.
27. Simultaneous analysis of serum α2,3-linked sialylation and core-type fucosylation of prostate-specific antigen for the detection of high-grade prostate cancer
28. Avelumab first-line maintenance plus best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma: JAVELIN Bladder 100 Japanese subgroup analysis
29. T-cell responses and combined immunotherapy against human carbonic anhydrase 9-expressing mouse renal cell carcinoma
30. Pembrolizumab plus axitinib versus sunitinib in metastatic renal cell carcinoma: outcomes of Japanese patients enrolled in the randomized, phase III, open-label KEYNOTE-426 study
31. Targeted-sequence of normal urothelium and tumor of patients with non-muscle invasive bladder cancer
32. Avelumab + axitinib vs sunitinib in patients (pts) with advanced renal cell carcinoma (aRCC): Final overall survival (OS) analysis from the JAVELIN Renal 101 phase 3 trial.
33. MP59-02 IMIDAZOLINE 2 RECEPTOR ACTIVATION IMPROVES DETRUSOR OVERACTIVITY OF MICE WITH SPINAL CORD INJURY THROUGH RELAXATION OF BLADDER SMOOTH MUSCLES
34. MP05-19 POLYGENETIC RISK SCORE FOR PROSTATE CANCER IS ASSOCIATED WITH LIPOPOLYSACCHARIDE PATHWAY IN GUT MICROBIOME
35. A Phase II, Randomized, Open-Label, Multi-arm Study of TAS-115 for Castration-Resistant Prostate Cancer Patients With Bone Metastases
36. Prognostic value of programmed death-ligand 1 status in Japanese patients with renal cell carcinoma
37. A novel prediction model for the completion of six cycles of radium-223 treatment and survival in patients with metastatic castration-resistant prostate cancer
38. Real-world safety and effectiveness of radium-223 in Japanese patients with castration-resistant prostate cancer (CRPC) and bone metastasis: exploratory analysis, based on the results of post-marketing surveillance, according to prior chemotherapy status and in patients without concomitant use of second-generation androgen-receptor axis-targeted agents
39. Outcome of primary androgen deprivation therapy in super-elderly men with localized high-risk prostate cancer
40. Hypoxia‐related carbonic anhydrase 9 induces serpinB9 expression in cancer cells and apoptosis in T cells via acidosis
41. Comparison of the Efficacy of Enfortumab Vedotin between patients with Metastatic Urothelial Carcinoma who were treated with Avelumab or Pembrolizumab: Real-World Data from a Multi-Institutional Study in Japan
42. Inflammatory myofibroblastic tumor of the prostate
43. Moving toward improved immune checkpoint immunotherapy for advanced prostate cancer
44. Efficacy and safety of darolutamide in Japanese patients with nonmetastatic castration-resistant prostate cancer: a sub-group analysis of the phase III ARAMIS trial
45. A multicenter retrospective study of nivolumab monotherapy in previously treated metastatic renal cell carcinoma patients: interim analysis of Japanese real-world data
46. Chemopreventive effects of nanoparticle curcumin in a mouse model of Pten-deficient prostate cancer
47. Mixed 20-peptide cancer vaccine in combination with docetaxel and dexamethasone for castration-resistant prostate cancer: a randomized phase II trial
48. A randomized, double-blind, comparison of radium-223 and placebo, in combination with abiraterone acetate and prednisolone, in castration-resistant metastatic prostate cancer: subgroup analysis of Japanese patients in the ERA 223 study
49. Immune Therapy for Castration-Resistant Prostate Cancer
50. Prediction of Optimal Number of Cycles in Docetaxel Regimen for Patients with mCRPC
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.